CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients

CONCLUSION AND RELEVANCE: The median C0/D values were 90.38% higher in kidney transplant recipients with CYP3A5*3/*3 genotype than in those with CYP3A5*1/*1 or CYP3A5*1/*3 genotype when treated with both tacrolimus and voriconazole. A CYP3A5 genotype-dependent DDI was found between tacrolimus and voriconazole. Therefore, personalized therapy accounting for CYP3A5 genotype detection and therapeutic drug monitoring is necessary for kidney transplant patients when treating with tacrolimus and voriconazole.PMID:37702380 | DOI:10.1177/10600280231197399

Source: The Annals of Pharmacotherapy - September 13, 2023 Category: Drugs & Pharmacology Authors: Yundi Zhang Yue Du Shuyu Ren Yue Li Xiaoming Zhang Xiaohong Cao Fengxi Liu Huiying Zong Yan Li Source Type: research